Quinpramine is a novel compound effective in ameliorating brain autoimmune disease

Research output: Contribution to journalArticle

Mahendra P. Singh, Gerd Meyer zu Hörste, Wei Hu, Anne K. Mausberg, Petra D. Cravens, Todd N. Eagar, Stefan Löber, Ralf Klingenstein, Peter Gmeiner, Carsten Korth, Bernd C. Kieseier, Olaf Stüve

Acridine-iminodibenzyl chimeric compounds were previously introduced as a class of cholesterol-redistributing substances with antiprion effects. Here, we show that administration of the lead compound quinpramine to mice with experimental autoimmune encephalitis, an animal model of multiple sclerosis (MS), significantly ameliorates disease in preventive and therapeutic paradigms. Quinpramine treatment decreased the number of inflammatory CNS lesions, antigen-specific T-cell proliferation, and pro-inflammatory cytokines IFNγ and IL-17. Quinpramine is thus an immunoregulatory drug that is a candidate pharmaceutical for MS.

Original languageEnglish (US)
Pages (from-to)397-400
Number of pages4
JournalExperimental Neurology
Volume215
Issue number2
DOIs
StatePublished - Feb 1 2009

PMID: 18996373

Altmetrics

Cite this

Standard

Quinpramine is a novel compound effective in ameliorating brain autoimmune disease. / Singh, Mahendra P.; Hörste, Gerd Meyer zu; Hu, Wei; Mausberg, Anne K.; Cravens, Petra D.; Eagar, Todd N.; Löber, Stefan; Klingenstein, Ralf; Gmeiner, Peter; Korth, Carsten; Kieseier, Bernd C.; Stüve, Olaf.

In: Experimental Neurology, Vol. 215, No. 2, 01.02.2009, p. 397-400.

Research output: Contribution to journalArticle

Harvard

Singh, MP, Hörste, GMZ, Hu, W, Mausberg, AK, Cravens, PD, Eagar, TN, Löber, S, Klingenstein, R, Gmeiner, P, Korth, C, Kieseier, BC & Stüve, O 2009, 'Quinpramine is a novel compound effective in ameliorating brain autoimmune disease' Experimental Neurology, vol. 215, no. 2, pp. 397-400. https://doi.org/10.1016/j.expneurol.2008.10.001

APA

Singh, M. P., Hörste, G. M. Z., Hu, W., Mausberg, A. K., Cravens, P. D., Eagar, T. N., ... Stüve, O. (2009). Quinpramine is a novel compound effective in ameliorating brain autoimmune disease. Experimental Neurology, 215(2), 397-400. https://doi.org/10.1016/j.expneurol.2008.10.001

Vancouver

Singh MP, Hörste GMZ, Hu W, Mausberg AK, Cravens PD, Eagar TN et al. Quinpramine is a novel compound effective in ameliorating brain autoimmune disease. Experimental Neurology. 2009 Feb 1;215(2):397-400. https://doi.org/10.1016/j.expneurol.2008.10.001

Author

Singh, Mahendra P. ; Hörste, Gerd Meyer zu ; Hu, Wei ; Mausberg, Anne K. ; Cravens, Petra D. ; Eagar, Todd N. ; Löber, Stefan ; Klingenstein, Ralf ; Gmeiner, Peter ; Korth, Carsten ; Kieseier, Bernd C. ; Stüve, Olaf. / Quinpramine is a novel compound effective in ameliorating brain autoimmune disease. In: Experimental Neurology. 2009 ; Vol. 215, No. 2. pp. 397-400.

BibTeX

@article{1e23b315ce8c49358422fa8299eb40b6,
title = "Quinpramine is a novel compound effective in ameliorating brain autoimmune disease",
abstract = "Acridine-iminodibenzyl chimeric compounds were previously introduced as a class of cholesterol-redistributing substances with antiprion effects. Here, we show that administration of the lead compound quinpramine to mice with experimental autoimmune encephalitis, an animal model of multiple sclerosis (MS), significantly ameliorates disease in preventive and therapeutic paradigms. Quinpramine treatment decreased the number of inflammatory CNS lesions, antigen-specific T-cell proliferation, and pro-inflammatory cytokines IFNγ and IL-17. Quinpramine is thus an immunoregulatory drug that is a candidate pharmaceutical for MS.",
author = "Singh, {Mahendra P.} and H{\"o}rste, {Gerd Meyer zu} and Wei Hu and Mausberg, {Anne K.} and Cravens, {Petra D.} and Eagar, {Todd N.} and Stefan L{\"o}ber and Ralf Klingenstein and Peter Gmeiner and Carsten Korth and Kieseier, {Bernd C.} and Olaf St{\"u}ve",
year = "2009",
month = "2",
day = "1",
doi = "10.1016/j.expneurol.2008.10.001",
language = "English (US)",
volume = "215",
pages = "397--400",
journal = "Experimental Neurology",
issn = "0014-4886",
publisher = "Academic Press",
number = "2",

}

RIS

TY - JOUR

T1 - Quinpramine is a novel compound effective in ameliorating brain autoimmune disease

AU - Singh, Mahendra P.

AU - Hörste, Gerd Meyer zu

AU - Hu, Wei

AU - Mausberg, Anne K.

AU - Cravens, Petra D.

AU - Eagar, Todd N.

AU - Löber, Stefan

AU - Klingenstein, Ralf

AU - Gmeiner, Peter

AU - Korth, Carsten

AU - Kieseier, Bernd C.

AU - Stüve, Olaf

PY - 2009/2/1

Y1 - 2009/2/1

N2 - Acridine-iminodibenzyl chimeric compounds were previously introduced as a class of cholesterol-redistributing substances with antiprion effects. Here, we show that administration of the lead compound quinpramine to mice with experimental autoimmune encephalitis, an animal model of multiple sclerosis (MS), significantly ameliorates disease in preventive and therapeutic paradigms. Quinpramine treatment decreased the number of inflammatory CNS lesions, antigen-specific T-cell proliferation, and pro-inflammatory cytokines IFNγ and IL-17. Quinpramine is thus an immunoregulatory drug that is a candidate pharmaceutical for MS.

AB - Acridine-iminodibenzyl chimeric compounds were previously introduced as a class of cholesterol-redistributing substances with antiprion effects. Here, we show that administration of the lead compound quinpramine to mice with experimental autoimmune encephalitis, an animal model of multiple sclerosis (MS), significantly ameliorates disease in preventive and therapeutic paradigms. Quinpramine treatment decreased the number of inflammatory CNS lesions, antigen-specific T-cell proliferation, and pro-inflammatory cytokines IFNγ and IL-17. Quinpramine is thus an immunoregulatory drug that is a candidate pharmaceutical for MS.

UR - http://www.scopus.com/inward/record.url?scp=58149481475&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149481475&partnerID=8YFLogxK

U2 - 10.1016/j.expneurol.2008.10.001

DO - 10.1016/j.expneurol.2008.10.001

M3 - Article

VL - 215

SP - 397

EP - 400

JO - Experimental Neurology

T2 - Experimental Neurology

JF - Experimental Neurology

SN - 0014-4886

IS - 2

ER -

ID: 16808175